The inaugural cohort of JPOD resident companies, which J&J will support in various capacities from concept to commercialization. The seven early-stage startups are treating glaucoma, reconstructing peripheral nerves, developing brain stimulation therapies, and much, much more.
Avisi Technologies is developing VisiPlate to treat glaucoma, the world’s leading cause of irreversible blindness. VisiPlate is a nanotechnology-enabled ocular implant for treating glaucoma more safely and effectively.
In front of a standing-room-only crowd in the Singh Center’s Glandt Forum this week, four teams made their pitches for how to turn technology developed by Penn Engineers into the next big thing. Each year, the Mack Institute, Penn Engineering, Penn Wharton Entrepreneurship, and the Penn Center for Innovation come together for the invention competition […]
A subset of 25 early-stage companies will participate in MedTech Innovator’s award-winning Accelerator program, in which MedTech startups are matched with senior industry leaders to receive in-depth, customized mentorship and support. With a competitive 3% acceptance rate, the selection process for this year’s program set a high bar for applicants. Together with the senior leadership teams of its corporate partners and over 200 industry judges, MedTech Innovator traveled to evaluate over 150 candidates in person out of over 800 applications from 34 countries and 45 U.S. states.
